Brief: Vertex And Ono Pharmaceutical Announce Strategic Agreement To Develop & Commercialize Povetacicept In Japan & South Korea
23/06/2025 10:39
June 23 (Reuters) - Vertex Pharmaceuticals: VERTEX AND ONO PHARMACEUTICAL ANNOUNCE STRATEGIC AGREEMENT TO DEVELOP AND COMMERCIALIZE POVETACICEPT IN JAPAN AND SOUTH KOREA VERTEX PHARMACEUTICALS: WILL RECEIVE AN UPFRONT PAYMENT, AS WELL AS CERTAIN REGULATORY AND COMMERCIAL MILESTONE PAYMENTS AND TIERED ROYALTIES Source text: ID:nBwm1mnca Further company coverage: 4528.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours